Post-acute effectiveness of lithium in pediatric bipolar i disorder

Robert L Findling, Vivian Kafantaris, Mani Pavuluri, Nora K. McNamara, Jean A. Frazier, Linmarie Sikich, Robert Kowatch, Brieana M. Rowles, Traci E. Clemons, Perdita Taylor-Zapata

Research output: Contribution to journalArticle

Abstract

Objective: This study examined the long-term effectiveness of lithium for the treatment of pediatric bipolar disorder within the context of combination mood stabilizer therapy for refractory mania and pharmacological treatment of comorbid psychiatric conditions. Methods: Outpatients, ages 7-17 years, meeting American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnostic criteria for bipolar disorder I (BP-I) (manic or mixed) who demonstrated at least a partial response to 8 weeks of open-label treatment with lithium (Phase I) were eligible to receive open-label lithium for an additional 16 weeks (Phase II). Up to two adjunctive medications could be prescribed to patients experiencing residual symptoms of mania or comorbid psychiatric conditions, following a standardized algorithm. Results: Forty-one patients received continued open-label long-term treatment with lithium for a mean of 14.9 (3.0) weeks during Phase II. The mean weight-adjusted total daily dose at end of Phase II was 27.8 (6.7) mg/kg/day, with an average lithium concentration of 1.0 (0.3) mEq/L. Twenty-five of the 41 patients (60.9%) were prescribed adjunctive psychotropic medications for residual symptoms. The most frequent indications for adjunctive medications were refractory mania (n=13; 31.7%) and attention-deficit/hyperactivity disorder (ADHD) (n=15; 36.6%). At the end of this phase 28 (68.3%) patients met a priori criteria for response (≥50% reduction from Phase I baseline in Young Mania Rating Scale [YMRS] summary score and a Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2), with 22 (53.7%) considered to be in remission (YMRS summary score≤12 and CGI-Severity score of 1 or 2). These data suggest that patients who initially responded to lithium maintained mood stabilization during continuation treatment, but partial responders did not experience further improvement during Phase II, despite the opportunity to receive adjunctive medications. The most commonly reported (≥20%) adverse events associated with lithium treatment were vomiting, headache, abdominal pain, and tremor. Conclusions: Lithium may be a safe and effective longer-term treatment for patients with pediatric bipolar disorder who respond to acute treatment with lithium. Partial responders to acute lithium did not appear to experience substantial symptom improvement during the continuation phase, despite the possibility that adjunctive medications could be prescribed.

Original languageEnglish (US)
Pages (from-to)80-90
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume23
Issue number2
DOIs
StatePublished - Mar 1 2013

Fingerprint

Bipolar Disorder
Lithium
Pediatrics
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry
Tremor
Attention Deficit Disorder with Hyperactivity
Abdominal Pain
Vomiting
Headache
Outpatients
Pharmacology
Weights and Measures

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Findling, R. L., Kafantaris, V., Pavuluri, M., McNamara, N. K., Frazier, J. A., Sikich, L., ... Taylor-Zapata, P. (2013). Post-acute effectiveness of lithium in pediatric bipolar i disorder. Journal of Child and Adolescent Psychopharmacology, 23(2), 80-90. https://doi.org/10.1089/cap.2012.0063

Post-acute effectiveness of lithium in pediatric bipolar i disorder. / Findling, Robert L; Kafantaris, Vivian; Pavuluri, Mani; McNamara, Nora K.; Frazier, Jean A.; Sikich, Linmarie; Kowatch, Robert; Rowles, Brieana M.; Clemons, Traci E.; Taylor-Zapata, Perdita.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 23, No. 2, 01.03.2013, p. 80-90.

Research output: Contribution to journalArticle

Findling, RL, Kafantaris, V, Pavuluri, M, McNamara, NK, Frazier, JA, Sikich, L, Kowatch, R, Rowles, BM, Clemons, TE & Taylor-Zapata, P 2013, 'Post-acute effectiveness of lithium in pediatric bipolar i disorder', Journal of Child and Adolescent Psychopharmacology, vol. 23, no. 2, pp. 80-90. https://doi.org/10.1089/cap.2012.0063
Findling, Robert L ; Kafantaris, Vivian ; Pavuluri, Mani ; McNamara, Nora K. ; Frazier, Jean A. ; Sikich, Linmarie ; Kowatch, Robert ; Rowles, Brieana M. ; Clemons, Traci E. ; Taylor-Zapata, Perdita. / Post-acute effectiveness of lithium in pediatric bipolar i disorder. In: Journal of Child and Adolescent Psychopharmacology. 2013 ; Vol. 23, No. 2. pp. 80-90.
@article{3f71ff62b0d64008804937bddd7c4a2a,
title = "Post-acute effectiveness of lithium in pediatric bipolar i disorder",
abstract = "Objective: This study examined the long-term effectiveness of lithium for the treatment of pediatric bipolar disorder within the context of combination mood stabilizer therapy for refractory mania and pharmacological treatment of comorbid psychiatric conditions. Methods: Outpatients, ages 7-17 years, meeting American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnostic criteria for bipolar disorder I (BP-I) (manic or mixed) who demonstrated at least a partial response to 8 weeks of open-label treatment with lithium (Phase I) were eligible to receive open-label lithium for an additional 16 weeks (Phase II). Up to two adjunctive medications could be prescribed to patients experiencing residual symptoms of mania or comorbid psychiatric conditions, following a standardized algorithm. Results: Forty-one patients received continued open-label long-term treatment with lithium for a mean of 14.9 (3.0) weeks during Phase II. The mean weight-adjusted total daily dose at end of Phase II was 27.8 (6.7) mg/kg/day, with an average lithium concentration of 1.0 (0.3) mEq/L. Twenty-five of the 41 patients (60.9{\%}) were prescribed adjunctive psychotropic medications for residual symptoms. The most frequent indications for adjunctive medications were refractory mania (n=13; 31.7{\%}) and attention-deficit/hyperactivity disorder (ADHD) (n=15; 36.6{\%}). At the end of this phase 28 (68.3{\%}) patients met a priori criteria for response (≥50{\%} reduction from Phase I baseline in Young Mania Rating Scale [YMRS] summary score and a Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2), with 22 (53.7{\%}) considered to be in remission (YMRS summary score≤12 and CGI-Severity score of 1 or 2). These data suggest that patients who initially responded to lithium maintained mood stabilization during continuation treatment, but partial responders did not experience further improvement during Phase II, despite the opportunity to receive adjunctive medications. The most commonly reported (≥20{\%}) adverse events associated with lithium treatment were vomiting, headache, abdominal pain, and tremor. Conclusions: Lithium may be a safe and effective longer-term treatment for patients with pediatric bipolar disorder who respond to acute treatment with lithium. Partial responders to acute lithium did not appear to experience substantial symptom improvement during the continuation phase, despite the possibility that adjunctive medications could be prescribed.",
author = "Findling, {Robert L} and Vivian Kafantaris and Mani Pavuluri and McNamara, {Nora K.} and Frazier, {Jean A.} and Linmarie Sikich and Robert Kowatch and Rowles, {Brieana M.} and Clemons, {Traci E.} and Perdita Taylor-Zapata",
year = "2013",
month = "3",
day = "1",
doi = "10.1089/cap.2012.0063",
language = "English (US)",
volume = "23",
pages = "80--90",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Post-acute effectiveness of lithium in pediatric bipolar i disorder

AU - Findling, Robert L

AU - Kafantaris, Vivian

AU - Pavuluri, Mani

AU - McNamara, Nora K.

AU - Frazier, Jean A.

AU - Sikich, Linmarie

AU - Kowatch, Robert

AU - Rowles, Brieana M.

AU - Clemons, Traci E.

AU - Taylor-Zapata, Perdita

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Objective: This study examined the long-term effectiveness of lithium for the treatment of pediatric bipolar disorder within the context of combination mood stabilizer therapy for refractory mania and pharmacological treatment of comorbid psychiatric conditions. Methods: Outpatients, ages 7-17 years, meeting American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnostic criteria for bipolar disorder I (BP-I) (manic or mixed) who demonstrated at least a partial response to 8 weeks of open-label treatment with lithium (Phase I) were eligible to receive open-label lithium for an additional 16 weeks (Phase II). Up to two adjunctive medications could be prescribed to patients experiencing residual symptoms of mania or comorbid psychiatric conditions, following a standardized algorithm. Results: Forty-one patients received continued open-label long-term treatment with lithium for a mean of 14.9 (3.0) weeks during Phase II. The mean weight-adjusted total daily dose at end of Phase II was 27.8 (6.7) mg/kg/day, with an average lithium concentration of 1.0 (0.3) mEq/L. Twenty-five of the 41 patients (60.9%) were prescribed adjunctive psychotropic medications for residual symptoms. The most frequent indications for adjunctive medications were refractory mania (n=13; 31.7%) and attention-deficit/hyperactivity disorder (ADHD) (n=15; 36.6%). At the end of this phase 28 (68.3%) patients met a priori criteria for response (≥50% reduction from Phase I baseline in Young Mania Rating Scale [YMRS] summary score and a Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2), with 22 (53.7%) considered to be in remission (YMRS summary score≤12 and CGI-Severity score of 1 or 2). These data suggest that patients who initially responded to lithium maintained mood stabilization during continuation treatment, but partial responders did not experience further improvement during Phase II, despite the opportunity to receive adjunctive medications. The most commonly reported (≥20%) adverse events associated with lithium treatment were vomiting, headache, abdominal pain, and tremor. Conclusions: Lithium may be a safe and effective longer-term treatment for patients with pediatric bipolar disorder who respond to acute treatment with lithium. Partial responders to acute lithium did not appear to experience substantial symptom improvement during the continuation phase, despite the possibility that adjunctive medications could be prescribed.

AB - Objective: This study examined the long-term effectiveness of lithium for the treatment of pediatric bipolar disorder within the context of combination mood stabilizer therapy for refractory mania and pharmacological treatment of comorbid psychiatric conditions. Methods: Outpatients, ages 7-17 years, meeting American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnostic criteria for bipolar disorder I (BP-I) (manic or mixed) who demonstrated at least a partial response to 8 weeks of open-label treatment with lithium (Phase I) were eligible to receive open-label lithium for an additional 16 weeks (Phase II). Up to two adjunctive medications could be prescribed to patients experiencing residual symptoms of mania or comorbid psychiatric conditions, following a standardized algorithm. Results: Forty-one patients received continued open-label long-term treatment with lithium for a mean of 14.9 (3.0) weeks during Phase II. The mean weight-adjusted total daily dose at end of Phase II was 27.8 (6.7) mg/kg/day, with an average lithium concentration of 1.0 (0.3) mEq/L. Twenty-five of the 41 patients (60.9%) were prescribed adjunctive psychotropic medications for residual symptoms. The most frequent indications for adjunctive medications were refractory mania (n=13; 31.7%) and attention-deficit/hyperactivity disorder (ADHD) (n=15; 36.6%). At the end of this phase 28 (68.3%) patients met a priori criteria for response (≥50% reduction from Phase I baseline in Young Mania Rating Scale [YMRS] summary score and a Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2), with 22 (53.7%) considered to be in remission (YMRS summary score≤12 and CGI-Severity score of 1 or 2). These data suggest that patients who initially responded to lithium maintained mood stabilization during continuation treatment, but partial responders did not experience further improvement during Phase II, despite the opportunity to receive adjunctive medications. The most commonly reported (≥20%) adverse events associated with lithium treatment were vomiting, headache, abdominal pain, and tremor. Conclusions: Lithium may be a safe and effective longer-term treatment for patients with pediatric bipolar disorder who respond to acute treatment with lithium. Partial responders to acute lithium did not appear to experience substantial symptom improvement during the continuation phase, despite the possibility that adjunctive medications could be prescribed.

UR - http://www.scopus.com/inward/record.url?scp=84875431653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875431653&partnerID=8YFLogxK

U2 - 10.1089/cap.2012.0063

DO - 10.1089/cap.2012.0063

M3 - Article

C2 - 23510444

AN - SCOPUS:84875431653

VL - 23

SP - 80

EP - 90

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -